TFF Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
January 07 2021 - 9:01AM
Business Wire
Corporate presentation available on demand
beginning Monday, January 11, 2021 at 6:00 AM ET
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative drug products based on its patented Thin Film Freezing
(TFF) technology platform, has been invited to present at H.C.
Wainwright’s BioConnect 2021 Conference, being held virtually on
January 11-14, 2021.
Glenn Mattes, President & CEO of TFF Pharmaceuticals, is
scheduled to give a pre-recorded company presentation to conference
attendees. The recording will be available on-demand via the H.C.
Wainwright conference portal for one week and can be accessed in
the Investor Relations section at TFF Pharmaceuticals beginning on
Monday, January 11 at 6:00 AM Eastern time.
In addition, the Company will meet with investors at the Biotech
Showcase, an event also taking place virtually from January 11-15,
as well as participating in investor and partnering meetings
through the Biotechnology Innovation Organization’s (BIO)
One-on-One Partnering System throughout the week.
About TFF Pharmaceuticals’ Thin Film Freezing technology
platform TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform
was designed to improve the solubility and absorption of poorly
water-soluble drugs and is particularly suited to generate dry
powder particles with properties targeted for inhalation delivery,
especially to the deep lung, an area of extreme interest in
respiratory medicine. The TFF process results in a “Brittle Matrix
Particle,” which possesses low bulk density, high surface area, and
typically an amorphous morphology, allowing the particles to
supersaturate when contacting the target site, such as lung tissue.
Based upon laboratory experiments the aerodynamic properties of the
particles are such that the portion of a drug deposited to the deep
lung has the potential to reach as high as 75 percent.
About TFF Pharmaceuticals TFF Pharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company focused on developing and
commercializing innovative drug products based on its patented Thin
Film Freezing, or TFF, technology platform. Early testing confirms
that the TFF platform can significantly improve the solubility and
absorption of poorly water-soluble drugs, a class of drugs that
comprises approximately one-third of the major pharmaceuticals
worldwide, thereby improving their pharmacokinetics. TFF
Pharmaceuticals has two lead drug candidates: Voriconazole
Inhalation Powder and Tac-Lac Inhalation Powder. The Company plans
to add to this pipeline by collaborating with large pharmaceutical
partners. The TFF Platform is protected by 42 patents issued or
pending in the US and internationally. To learn more about TFF
Pharmaceuticals and its product candidates, visit the Company’s
website at https://tffpharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210107005546/en/
Company Contacts: Glenn Mattes President and CEO TFF
Pharmaceuticals, Inc. gmattes@tffpharma.com 737-802-1973
Kirk Coleman Chief Financial Officer TFF Pharmaceuticals, Inc.
kcoleman@tffpharma.com 817-989-6358
Investor Relations and Media Contact: Paul Sagan
LaVoieHealthScience psagan@lavoiehealthscience.com 617-953-4779
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
From Mar 2024 to Apr 2024
TFF Pharmaceuticals (NASDAQ:TFFP)
Historical Stock Chart
From Apr 2023 to Apr 2024